Takeda Pharmaceutical Company Limited or HUTCHMED (China) Limited: Who Invests More in Innovation?

Takeda vs. HUTCHMED: R&D Investment Showdown

__timestampHUTCHMED (China) LimitedTakeda Pharmaceutical Company Limited
Wednesday, January 1, 201433472000382096000000
Thursday, January 1, 201547368000345927000000
Friday, January 1, 201666871000312303000000
Sunday, January 1, 201750675000325441000000
Monday, January 1, 201878821000368298000000
Tuesday, January 1, 201991944000492381000000
Wednesday, January 1, 2020111234000455833000000
Friday, January 1, 2021207447000526087000000
Saturday, January 1, 2022267587000633325000000
Sunday, January 1, 2023303055000729924000000
Monday, January 1, 2024729924000000
Loading chart...

Cracking the code

Innovation Investment: A Tale of Two Companies

In the competitive world of pharmaceuticals, innovation is key. Takeda Pharmaceutical Company Limited and HUTCHMED (China) Limited are two giants in this arena, each with a distinct approach to research and development (R&D) investment. Over the past decade, Takeda has consistently outpaced HUTCHMED, investing nearly 3,000% more in R&D annually. In 2023, Takeda's R&D expenses reached a staggering $730 billion, while HUTCHMED's were approximately $303 million. This trend highlights Takeda's commitment to innovation, with a steady increase in R&D spending since 2014. Meanwhile, HUTCHMED has shown significant growth, with a nearly 900% increase in R&D expenses over the same period. As we look to the future, the question remains: will HUTCHMED close the gap, or will Takeda continue to lead the charge in pharmaceutical innovation?

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025